Understand the source comparison
Dihexa Alternatives 2026: Peptide Comparison
| Peptide | Primary Mechanism | Receptor Target | Half-Life (Plasma) | Typical Research Dose Range | Blood-Brain Barrier Penetration | Professional Assessment ||—|—|—|—|—|—|| Cerebrolysin | Neurotrophic factor upregulation (BDNF, NGF) | TrkB, TrkA | 6–8 hours
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Primary Mechanism | Receptor Target | Half-Life (Plasma) | Typical Research Dose Range | Blood-Brain Barrier Penetration | Professional Assessment ||—|—|—|—|—|—|| Cerebrolysin | Neurotrophic factor upregulation (BDNF, NGF) | TrkB, TrkA | 6–8 hours | 2.5–5 mL/kg (rodent, IP) | Moderate (15–20%) | Best for structural plasticity studies requiring trophic support. Multi-factor mechanism covers BDNF and NGF pathways Dihexa doesn't engage || P21 | CREB phosphorylation via PKA activation | CREB transcription factor | 4–6 hours | 0.5–2 mg/kg (rodent, SC/IP) | Moderate (12–18%) | Optimal for LTP and memory consolidation research. Bypasses receptor dependency but requires concurrent structural support for full effect || Semax | Dopamine receptor density modulation | MC3R, MC4R, D1/D2 receptors | 1–2 hours | 0.3–1 mg/kg (rodent, intranasal) | Low (5–10%) | Targets monoamine receptor expression gaps. Ideal for dopamine depletion models but limited structural plasticity contribution ||